Patent ID: 6262119
Filing Date: 2001-07-17
Classification: A61K,A61P,Y10S

Abstract:
A method of treating or ameliorating symptoms of T-cell mediated disease in a subject, the method comprising administering to the subject a composition comprising a therapeutically effective amount of a polyunsaturated fatty acid and a pharmaceutically acceptable carrier; in which the polyunsaturated fatty acid contains 18-25 carbons, 1-6 double bonds and has one or two substitutions selected from the group consisting of .beta. oxa, .gamma. oxa, .beta. thia and .gamma. thia, based on the fatty acid acyl carbon, wherein said T-cell mediated disease is selected from the group consisting of diabetes multiple sclerosis, rheumatoid arthritis, herpes simplex, stromal keratitis, psoriasis, Crohn's disease, inflammatory bowel disease, graft vs. host disease, scleroderma, asthma, rhinitis, eczema, atoptic dermatitis, allergic diseases, systemic lupus, erythematosis and polymyositis.